HOME >> BIOLOGY >> NEWS
New strategy rapidly identifies cancer targets

In a step toward personalized medicine, Howard Hughes Medical Institute investigator Brian J. Druker and colleagues have developed a new technique to identify previously unknown genetic mutations that can trigger cancerous growth. By analyzing the proteins instead of the genes inside acute myeloid leukemia (AML) cells, the researchers have dramatically reduced the time it takes to zero in on molecular abnormalities that might be vulnerable to specific drug treatments.

"This approach gives us a way to figure out what's driving the growth of a cancer in an individual patient and ultimately match that patient with the right drug," said Druker, who is based at the Oregon Health & Science University in Portland. Druker's team collaborated on the research, which was published in the July 17, 2006, issue of the journal Cancer Cell, with scientists in the lab of D. Gary Gilliland, an HHMI investigator at Brigham and Women's Hospital, as well as researchers at the Portland VA Medical Center, Cell Signaling Technology, the University of Chicago, and Yale University.

Traditionally, cancer-gene hunters have scanned the genome looking for mutations that trigger out-of-control cell growth. Druker tried this approach, but found it wanting. "We were doing some high-throughput DNA sequencing, and we weren't really finding much," he said.

Instead, the team added tools from the burgeoning field of proteomics, the study of proteins. "We decided this more functional assay would get us to the disease-causing genes more rapidly," said Druker, who has been studying a group of cell-signaling proteins called tyrosine kinases for 20 years.

Tyrosine kinases play a key role in many cancers. In healthy cells, they help form a chain of signals that prompt normal cell growth and division. Sometimes, though, a tyrosine kinase gets stuck in an "on" position, driving out-of-control cell division and, ultimately, cancer. This potentially devastating kinase act
'"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
16-Jul-2006


Page: 1 2 3

Related biology news :

1. New strategy for treating allergic disorders
2. Does EPA have an adequate strategy to oversee nanotechnologies?
3. High blood pressure medication strategy proves effective in Hispanic women
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Scientists identify new strategy for preventing acute and chronic brain disease
6. International risk research strategy and funding needed for nanotech safety
7. Study shows metabolic strategy of stressed cell
8. Trojan horse strategy defeats drug-resistant bacteria
9. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
10. Drug strategy makes cancer genes get lost in translation
11. Researchers develop new strategy for the treatment of CML

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New strategy rapidly identifies cancer targets

(Date:6/17/2013)... On June 6, professors in Wayne State ... National Science Foundation-funded (NSF) Research Experience for Undergraduates ... an opportunity to do cutting-edge research in astrophysics, ... According to Alexey Petrov, Ph.D., professor of physics ... principal investigator and program director of the grant, ...
(Date:6/17/2013)... a sugar alcohol produced by fungi, bacteria, and algae, ... The sweetener is also used in the medical field ... to flush out excess fluids and used during surgery ... ease the passage of other drugs. , Now Profs. ... Department of Molecular Microbiology and Biotechnology and the Sagol ...
(Date:6/17/2013)... method of mining shale gas, is widespread across Pennsylvania, ... New research in the Annals of the New ... to biodiversity including pollution from toxic chemicals, the building ... , "Shale gas has engendered a great deal of ... but effects on biological diversity and resources have scarcely ...
Breaking Biology News(10 mins):Wayne State welcomes undergraduates from around the US for physics research experience 2Artificial sweetener a potential treatment for Parkinson's disease 2
(Date:6/17/2013)... , June 17, 2013 /PRNewswire-iReach/ -- The ... Bob Riedford , President/Founder of Riedford Management, Inc. to its ... as a member of the Chamber,s Board of Advisors," said ... "This is one of the most prestigious positions to hold ... and experience our new board members will contribute." ...
(Date:6/16/2013)... This training is ideal for those who ... the software industry or those who want to explore Agile ... , The topics that will be covered in the 1-day ... meetings, scrum artifacts, and scrum simulation (optional). , The ... CO June 28, 2013 , Click here to register for ...
(Date:6/14/2013)... , June 14, 2013  Royalty Pharma notes today,s ... that it intends to explore a sale of the Company. ... that offers shareholders no certainty that a deal will ever be ... vote today AGAINST all four resolutions up for ... to preserve Royalty Pharma,s formal offer for Elan. In ...
(Date:6/14/2013)... The OpenClinica Global Conference is being ... with Formedix CEO, Mark Wheeldon presenting as part of ... deeper insight into the future developments at OpenClinica and ... to develop innovative solutions. , The conference program will ... hear real-life case studies and discover more about best ...
Breaking Biology Technology:Raleigh Chamber Names Bob Riedford to Board of Advisors 2Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 2Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 3Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 4Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 5Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 6Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 7Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 8Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 9Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 10Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 11Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 2Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 3
Cached News: